Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Feb;38(2):69-75.
doi: 10.1002/clc.22353. Epub 2015 Feb 2.

Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis

Affiliations
Comparative Study

Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis

Francesco Cappelli et al. Clin Cardiol. 2015 Feb.

Abstract

Background: Few studies have analyzed the clinical and echocardiographic differences between light-chain (AL) and transthyretin (TTR) amyloidosis.

Hypothesis: The aim of the present research was to compare, in a real-world setting, the clinical and echocardiographic profiles of these kinds of amyloidosis, at the time of diagnosis, using new-generation echocardiography.

Methods: Seventy-nine patients with AL and 48 patients with TTR amyloidosis were studied.

Results: According to the criterion of mean left ventricular (LV) thickness >12 mm, 45 AL (C-AL) and all TTR patients had cardiac amyloidotic involvement, whereas 34 AL patients did not. TTR patients had increased right ventricular (RV) and LV chambers with increased RV and LV wall thickness and reduced LV ejection fraction and fractional shortening. Furthermore, TTR patients showed lower N-terminal pro Brain Natriuretic Peptide concentrations and New York Heart Association functional class when compared with C-AL.

Conclusions: Our data show that at time of first diagnosis, TTR patients have a more advanced amyloidotic involvement of the heart, despite less severe symptoms and biohumoral signs of heart failure. We can hypothesize that we observed different diseases at different stages. In fact, AL amyloidosis is a multiorgan disease with quick progression rate, that becomes rapidly symptomatic, whereas TTR amyloidosis might have a slow progression rate and might remain poorly symptomatic for a greater amount of time.

PubMed Disclaimer

References

    1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–596. - PubMed
    1. Perfetto F, Cappelli F, Bergesio F, et al. Cardiac amyloidosis: the heart of the matter. Intern Emerg Med. 2013;8:191–203. - PubMed
    1. Smorti M, Cappelli F, Guarnieri S, et al. Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies. Psychol Health Med. 2014;19:263–272. - PubMed
    1. Smorti M, Cappelli F, Bergesio F, et al. Anxiety and depression among AL amyloidosis patients: the role of cardiac symptoms. Amyloid. 2012;19:123–128. - PubMed
    1. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203–1212. - PubMed

Publication types

MeSH terms

Supplementary concepts